Showing 2711-2720 of 5646 results for "".
- Cassini to Reveal New Cassini Device at ESCRShttps://modernod.com/news/cassini-to-reveal-new-cassini-device-at-the-escrs-in-paris/2476880/Cassini announced that it will reveal its new Cassini device at the 37th Congress of European Society of Cataract and Refractive Surgeons in Paris. This product introduction marks the next chapter of product design, with latest camera technology, improved patient comfort and great usability.
- Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMDhttps://modernod.com/news/kodiak-sciences-to-release-durability-data-from-clinical-development-program-of-ksi-301-for-wet-amd/2476877/Kodiak Sciences announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London. “Developing intra
- Registration Now Open for International Sports Vision Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-annual-conference/2476869/Registration is now open for Beyond 20/20, the 4th annual International Sports Vision Association (ISVA) conference, February 6-8, 2020, at the Bahia Resort Hotel in San Diego, California. “Sports Vision, the science of helping athletes reach peak levels of performance through t
- Oxurion Reports Additional Positive Topline Data from Phase 1 With THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DMEhttps://modernod.com/news/oxurion-reports-additional-positive-topline-data-from-phase-1-with-thr-149-a-novel-potent-plasma-kallikrein-inhibitor-for-dme/2476862/Oxurion reported additional positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). This phase 1 open-label, multicenter (US), non-randomized trial evaluated the safety of a single intra
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2479540/ProQR Therapeutics announced that it received fast track designation from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation
- Novartis Announces EU Approval of Lucentis for Preterm Infants With Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-announces-eu-approval-of-lucentis-for-preterm-infants-with-retinopathy-of-prematurity-rop/2476856/Novartis announced the European approval of Lucentis (ranibizumab) for preterm infants with retinopathy of prematurity (ROP), making it the first and only licensed pharmacological treatment for this indication. The approval is based on the landmark RAINBOW study, showing Lucentis is an eff
- Regenxbio Announces License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314https://modernod.com/news/regenxbio-announces-exclusive-worldwide-license-agreement-with-clearside-biomedical-for-evaluation-of-in-office-delivery-platform-for-rgx-314/2476851/Regenxbio and Clearside Biomedical announced an option and license agreement for exclusive worldwide rights to Clearside’s proprietary, in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (AMD), diabetic
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million
- Alimera Sciences Launches Iluvien in Germany For Noninfectious Uveitishttps://modernod.com/news/alimera-sciences-launches-iluvien-in-germany-for-noninfectious-uveitis/2476846/Alimera Sciences announced that it will immediately commence the launch of Iluvien in Germany for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is t
- Altered Visual Processing a Nonverbal Marker of Autism?https://modernod.com/news/altered-visual-processing-a-nonverbal-marker-of-autism/2476838/Patients with autism may have altered visual processing, which could serve as an objective, nonverbal neural marker of the disorder, new research suggests, according to a Medscape report. Using electroencephalography (EEG), investi